uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology. (BMS)
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology. (BMS)ORCID iD: 0000-0001-6120-2683
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology. (BMS)
2003 (English)In: Current Medicinal Chemistry, ISSN 0929-8673, E-ISSN 1875-533X, Vol. 10, no 22, 2447-60 p.Article in journal (Refereed) Published
Abstract [en]

Specific targeting of radionuclides is a promising approach to improve diagnosis and treatment of tumors. Targeting vectors may be monoclonal antibodies directed toward tumour-specific antigens or regulatory peptides binding to receptors overexpressed on or by malignant cells. Depending on the aim of the procedure and the biokinetics of the targeting vectors, radionuclides with different nuclear properties (decay scheme, half-life, etc.) must be applied. Halogen radioisotopes are attractive since they exhibit a variety of nuclear properties suitable for various applications. At the same time, their chemistry shows great similarities, which enables the use of similar labelling procedures for different nuclides. A problem in using radiohalogens for labelling of tumour-targeting proteins and peptides is that the commonly used radiohalogenation methods provide labels, which, after internalisation and lysosomal digestion, rapidly "leak" from malignant cells as radiohalogenated degradation products. The main reason for such leakage is free diffusion of the radiometabolites through lysosomal and cellular membranes. This review describes current approaches in molecular design to improve cellular retention of radiohalogen labels. These approaches include the use of prosthetic groups for the attachment of radiohalogens to targeting vectors of bulky hydrophilic non-charged molecules, molecules positively charged at lysosomal pH and negatively charged molecules. The emphasis in this paper is on labelling chemistry and the results of the biological testing of labelled compounds.

Place, publisher, year, edition, pages
2003. Vol. 10, no 22, 2447-60 p.
Keyword [en]
indirect radiohalogenation of proteins, radiobromine, radioiodine, astatine, tumor targeting, radioimmonotherapy, radioimmunodiagnosis, polyhedral boron anions
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-65699PubMedID: 14529484OAI: oai:DiVA.org:uu-65699DiVA: diva2:93610
Available from: 2008-10-17 Created: 2008-10-17 Last updated: 2017-11-28Bibliographically approved

Open Access in DiVA

No full text

PubMed

Authority records BETA

Tolmachev, VladimirOrlova, Anna

Search in DiVA

By author/editor
Tolmachev, VladimirOrlova, Anna
By organisation
Department of Oncology, Radiology and Clinical Immunology
In the same journal
Current Medicinal Chemistry
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

pubmed
urn-nbn

Altmetric score

pubmed
urn-nbn
Total: 526 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf